Are you crazy-- that was an awesome conference, even the food. I was really impressed with Isis management and significant pipeline. I feel really good about this investment, even Kynamro still has a green light going forward-- and could grab more market share then Aegr product. Very strong buy for ISIS. Short-term trading games being played-- but I can easily see ISIS trading above $13 in coming weeks.
Just hang in there, very positive presentation of ISIS at Lazard conference-- and well received. I bought after the conference myself. Stock could easily shoot up big in coming days, very little downside risk at this point. The really smart money however, is holding ISIS long-term.
the conference was another waste of time an shareholder's money. The ONLY potential blockbusters in the pipeline. --the metabolic drugs were not discussed and are 3-5 years away (If ever)....from fruition. The lousy management is reflected in the share price..Any other biotech Management would have this company in the$60s. Too many non-disclosures..example carcinogenicity. Of Kynamro.... Plus non performance. Survivin ,T 5000 and Affinitak are just a few exampleso